Treatment-resistant schizophrenia - The role of clozapine

Current Medical Research and Opinion

Volumn 14, Issue 1, 1997, Pages 1-20

  Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aetiology; Clozapine; Cognitive function; Disorganisation; Negative symptoms; Psychopathology; Quality of life; Schizophrenia; Suicidality; Tardive dyskinesia; Treatment resistant schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLOZAPINE; LITHIUM CARBONATE; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; VALPROIC ACID; ZIPRASIDONE;

BRAIN DISEASE; CAREGIVER; CLINICAL TRIAL; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; DRUG CHOICE; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; GENDER; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MENTAL HEALTH CARE; NEGATIVE SYNDROME; NEUROCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATIENT COMPLIANCE; PROLACTIN BLOOD LEVEL; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SOCIAL STATUS; SUICIDAL BEHAVIOR; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WORK CAPACITY;

EID: 0031417026     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999709113338     Document Type: Review

References (62)

1. Amsler HA, Teerenhovi L, Bartha E, Harjula K and Vuopio P (1977). Agranulocytosis in patients treated with clozapine: a study of the Finnish epidemic. Acta Psyclnatr. Scand., 56, 214-248.
2. Andreasen NC (1983). The Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, Iowa City, IA.
3. Angst J, Jaenicke U, Padrutt A and Scharfetter CH (1971). Ergbnisse eines Doppel-bindversuches von HF-1854 (8-chlor-11-[4-methyl-l-piperazinyl]-5-H-dibenzo[b,e][1,4]-diazepin) in vergleich zo levomepromazin. Pharmakopsychiatrie, 4, 192-200.
4. Breier A, Schreiber JL, Dyer J and Pickar D (1991). National Institute of Mental Health longitudinal study of chronic schizophrenia. Arch. Gen. Psychiatry, 48, 239-246.
5. Breier A, Buchanan RW, Kirkpatrick B, David OR, Irish D, Summerfeit A and Carpenter WT Jr (1994). Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry, 151, 20-26.
6. Buchanan RW, Holstein C and Breier A (1994). The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry, 36, 717-725.
7. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A and Tamminga CA (1995). Patient response and resource management: another view of clozapine treatment of schizophrenia. Am. J. Psychiatry, 152, 827-832.
8. Casey DE (1989). Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology, 99 (Suppl.), S47-S53.
9. Claas FH (1989). Drug-induced agranulocytosis: review of possible mechanisms, and prospects for clozapine studies. Psychopharmacobgy, 99 (Suppl.), S113-S117.
10. Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V and Klerman G (1987). The risks and benefits of clozapine versus chlorpromazine. J. Clin. Psychopharmacol, 7, 377-384.
11. Davis JM and Casper R (1977). Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs, 14, 260-282.
12. Drake GE, Gates C, Whitaker A and Cotton PG (1985). Suicide among schizophrenics: a review. Comp. Psychiatry, 26, 90-100.
13. Ekblom B and Haggstrom JE (1974). Clozapine (Leponex) compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties. Curr. Ther. Res. Clin. Exp., 16, 945-957.
14. Essock SM, Hargreaves WA, Dohm F-A, Goethe J, Carver L and Hipshman L (1996). Clozapine eligibility among state hospital patients. Schizophr. Bull, 22, 15-25.
15. Fisher-Cornelssen KA, Ferner UJ and Steiner H (1974). Multifokale Psychopharmaka-prufung ('Multi-hospital Trial'). Arzneimittel-Forschung, 24, 1706-1724.
16. Friedman L, Knutson L, Shurell M and Meltzer HY (1991). Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol Psychiatry, 29, 865-877.
17. Gelenberg AJ and Doller JC (1979). Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study. J. Clin. Psychiatry, 40, 238-240.
18. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC and Weinberg DR (1993). The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry, 162, 43-48.
19. Grace J, Bellus SB, Raulin ML, Herz MI, Priest BL, Brenner V, Donelly K, Smith P and Gunn S (1996). Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and social functioning. Psychiatric Services, 47, 41-45.
20. Guirguis E, Voineskos G, Gray J and Schlieman E (1977). Clozapine (Leponex) vs. chlorpromazine (Largactil) in acute schizophrenia (a double-blind controlled study). Curr. Ther. Res, 21, 707-719.
21. Guy W (1976).ECDEU assessment manual for psychopharmacology (ed.). DHEW Pub. No. (ADM) 76-338, National Institute of Mental Health, Rockville, MD.
22. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D and Meltzer HY (1993). Improvement in cognitive functions and psychiatric symptoms in treatmentrefractory schizophrenic patients receiving clozapine. Biol Psychiatry, 34, 702-712.
23. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C and Oepen G (1994). One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am. J. Psychiatry, 151(10), 1409-1416.
24. Heinrichs DW, Hanlon TE and Carpenter WT Jr (1984). The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull, 10, 388-396.
25. Helgason L (1990). Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatr, Scand., 81, 231-235.
26. Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS and Hargreaves WA (1995). Restricting clozapine use: the impact of stringent eligibility criteria. Psychiatric Services, 46, 801-806.
27. Kane J, Honigfeld G, Singer J and Meltzer HY (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry, 45, 789-796.
28. Lee MA, Hagger C, Thompson P and Meltzer HY (1994). Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry, 55 (Suppl. B), 91-93.
29. Lieberman J, Jody D, Geisler S, Alvir J and Loebel A (1993). Time course and biological correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry, 50, 369-376.
30. Lindström LH (1988). The effect of longterm treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr. Scand., 77, 524-529.
31. Loebel AD, Lieberman JA, Alvin J Jr, Mayerhoff DI, Geisler, SH and Szymanski SR (1992). Duration of psychosis and outcome in first-episode schizophrenia. Am. J. Psychiatry, 149, 1183-1188.
32. Macmillan JF, Crow T, Johnson AL and Johnstone EC (1986). Short-term outcome in trial entrants and trial eligible patients. Br. J. Psychiatry, 148, 128-133.
33. May PR, Tuma AH, Yale C, Potepan P and Dixon WJ (1976). Schizophrenia - a follow-up study of results of treatment. II: Hospital stay over two to five years, Arch. Gen. Psychiatry, 33, 481-486.
34. Meltzer HY (1990). Commentary: defining treatment refractoriness in schizophrenia. Schizophr. Bull, 16, 563-565.
35. Meltzer HY (1992). Dimensions of outcome with clozapine. Br. J. Psychiatry, 160 (Suppl. 17), 46-53.
36. Meltzer HY (1995). Is another view valid? Am. J. Psychiatry, 152, 821-825.
37. Meltzer HY, Goode DJ, Schyve PM, Young M and Fang VS (1979). Effect of clozapine on human serum prolactin levels. Am. J. Psychiatry, 136, 1550-1555.
38. Meltzer HY and Luchins DJ (1984). Effect of clozapine in severe tardive dyskinesia: A case report. J. Clin. Psychopharmacol, 4, 286-287.
39. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S and Sharpe J (1989). A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology, 99 (Suppl.), S68-S72.
40. Meltzer HY, Burnett S, Bastani B and Ramirez LF (1990). Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp. Comm. Psychiatry, 41, 892-897.
41. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies, MA and Snitz B (1993). Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am. J. Psychiatry, 150, 1630-1638.
42. Meltzer HY and Okayli G (1995). Reduction of suicidality during clozapine treatment in neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. Am. J. Psychiatry, 152, 183-190.
43. Meltzer HY, Lee MA, Ranjan R, Mason ED and Cola PA (1996). Relapse following clozapine withdrawal: effect of cyproheptadine plus neuroleptic. Psychopharmacol, 124, 176-187.
44. Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling R and Thompson PA (1997). Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am. J. Psychiatry, 154, 475-482.
45. Miller DD, Perry PJ, Cadoret RJ and Andreasen NC (1994). Clozapine's effects on negative symptoms in treatment-refractory schizophrenics. Comp. Psychiatry, 35, 8-15.
46. Nàhunek K, Rodovà A, Svestka J, Kamenickà V, Ceskovà E and Misurec J (1973). Clinical experience with clozapine in endogenous depression. Activ. Nerv. Sup. (Praha), 15, 102.
47. National Alliance for the Mentally 111, Newsletter, July 1986.
48. Overall JE and Gorham DR (1962). Brief Psychiatric Rating Scale. Psychological Reports, 10, 149-165.
49. Pickar D, Owen RR, Litman RE, Konicki, PE, Gutierrez L and Rapaport MH (1992). Clinical and biological response to clozapine in patients with schizophrenia. Arch. Gen. Psychiatry, 49, 345-353.
50. Povlsen UJ, Noring U, Fog R and Gerlach J (1985). Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr. Scand., 71, 176-185.
51. Ranjan R and Meltzer HY (1996). Acute and long term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry, 40(4), 253-258.
52. Reid WH, Mason M and Toprac M (1994). Savings in hospital bed-days related to treatment with clozapine. Hosp. Comm, Psychiatry, 45, 261-264.
53. Revicki DA, Luce BR, Wechsler JM, Brown RE and Adler MA (1990). Cost-effectiveness of clozapine for treatmentresistant schizophrenic patients. Hosp. Comm. Psychiatry, 41, 850-854.
54. Schmutz J and Eichenberger E (1982). Clozapine. In: Bindra JS and Lednicer D (Eds), Chronicles in Drug Discovery, Vol. 1, Wiley, New York, pp. 39-58.
55. Scottish Schizophrenia Research Group (1987). The Scottish First Episode Schizophrenia Study. Br. J. Psychiatry, 150, 331-344.
56. Shopsin B, Klein H, Aaronsom M and Collora M (1979). Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients. Arch. Gen. Psychiatry, 36, 657-664.
57. Singer K and Law SK (1974). A double-blind comparison of clozapine (Leponex) and chlorpromazine in schizophrenia of acute symptomatology. J. Intern. Med. Res., 2, 433-435.
58. Stoudemire A and Thompson T (1983). Medication noncompliance: systematic approaches to evaluation and intervention. Gen. Hosp. Psychiatry, 5, 233-239.
59. Strauss JS and Carpenter WT Jr (1972). The prediction of outcome in schizophrenia. I. Characteristics of outcome. Arch. Gen. Psychiatry, 27, 739-746.
60. Tandon R, Goldman R, DeQuardo JR, Goldman M, Ferez M and Jibson M (1993). Positive and negative symptoms covary during clozapine treatment in schizophrenia. J. Psychiatr. Res., 27, 341-347.
61. Wyatt RJ (1991). Neuroleptics and the natural course of schizophrenia. Schizophr. Bull, 17, 325-351.
62. Conley et al. (1998). In preparation.